Xenopat
www.xenopat.comThe orthotopic implantation of human tumors in mice allows Xenopat to provide services focused on assisting anticancer drug development and personalized oncologic treatment. Xenopat’s services focus on two main fields: Anticancer drug development. Xenopat offers to researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available nowadays. Xenopat offers these researchers the OrthoXenoBank®, composed of several orthotopic patient-derived xenografts (orthotopic PDXs, orthoxenografts®) of different tumor types, characterized at histological and genetic levels and with different sensitivity to diverse chemotherapies. Personalized oncologic treatment. Xenopat offers to healthcare professionals and patients the most advanced technology in order to select the best treatment in their fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model will allow Xenopat to test several drugs and find, the best therapy for each patient.
Read moreThe orthotopic implantation of human tumors in mice allows Xenopat to provide services focused on assisting anticancer drug development and personalized oncologic treatment. Xenopat’s services focus on two main fields: Anticancer drug development. Xenopat offers to researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available nowadays. Xenopat offers these researchers the OrthoXenoBank®, composed of several orthotopic patient-derived xenografts (orthotopic PDXs, orthoxenografts®) of different tumor types, characterized at histological and genetic levels and with different sensitivity to diverse chemotherapies. Personalized oncologic treatment. Xenopat offers to healthcare professionals and patients the most advanced technology in order to select the best treatment in their fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model will allow Xenopat to test several drugs and find, the best therapy for each patient.
Read moreCountry
City (Headquarters)
L'Hospitalet de Llobregat
Industry
Employees
1-10
Founded
2014
Social
Employees statistics
View all employeesPotential Decision Makers
Chief of Scientific Office and Co - Founder
Email ****** @****.comPhone (***) ****-****